Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 15/20 | 0.60 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2835672 | 1.00 | PIM1 (0.60) | PIM1CLK1DYRK2MEN1RAB9A | |
| SCHEMBL1559990 | 0.92 | PIM1 (0.51) | PIM1CLK1DYRK2MEN1RAB9A | |
| SCHEMBL1559987 | 0.92 | PIM1 (0.51) | PIM1CLK1DYRK2MEN1RAB9A | |
| SCHEMBL2834470 | 0.91 | PIM1 (0.66) | PIM1CLK1DYRK2MEN1RAB9A | |
| SCHEMBL2834464 | 0.91 | PIM1 (0.66) | PIM1CLK1DYRK2MEN1RAB9A | |
| SCHEMBL2833533 | 0.88 | PIM1 (0.53) | PIM1MEN1RAB9AKMT2ANPC1 | |
| SCHEMBL2833535 | 0.88 | PIM1 (0.53) | PIM1MEN1RAB9AKMT2ANPC1 | |
| SCHEMBL1558825 | 0.84 | PIM1 (0.67) | PIM1CLK1DYRK2 | |
| SCHEMBL1558818 | 0.84 | PIM1 (0.67) | PIM1CLK1DYRK2 | |
| SCHEMBL2835685 | 0.82 | MAPT (0.48) | PIM1CLK1DYRK2MEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2147912-A1 | Styrylquinolines, their process of preparation and their therapeutic uses | BioAlliance Pharma (FR) | 2010-01-27 | — | — | EP | claimed |
| US-20100120847-A1 | STYRYLQUINOLINES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES | BIOALLIANCE PHARMA (FR) | 2010-05-13 | — | — | US | disclosed |
| EP-2147912-A1 | Styrylquinolines, their process of preparation and their therapeutic uses | BioAlliance Pharma (FR) | 2010-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120847-A1 | STYRYLQUINOLINES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES | POLQ, PARP1, PARP14 | PIM1 19/4885CLK1 1817/4885DYRK2 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.